CN1980688A - 使肿瘤细胞致死的人α-乳清蛋白(HAMLET)在治疗病毒感染中的应用 - Google Patents

使肿瘤细胞致死的人α-乳清蛋白(HAMLET)在治疗病毒感染中的应用 Download PDF

Info

Publication number
CN1980688A
CN1980688A CNA2005800192369A CN200580019236A CN1980688A CN 1980688 A CN1980688 A CN 1980688A CN A2005800192369 A CNA2005800192369 A CN A2005800192369A CN 200580019236 A CN200580019236 A CN 200580019236A CN 1980688 A CN1980688 A CN 1980688A
Authority
CN
China
Prior art keywords
lactalbumin
alpha
biologically active
virus
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800192369A
Other languages
English (en)
Chinese (zh)
Inventor
C·斯范博格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamlet Pharma AB
Original Assignee
Hamlet Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamlet Pharma AB filed Critical Hamlet Pharma AB
Publication of CN1980688A publication Critical patent/CN1980688A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2005800192369A 2004-04-20 2005-04-20 使肿瘤细胞致死的人α-乳清蛋白(HAMLET)在治疗病毒感染中的应用 Pending CN1980688A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0408752.4A GB0408752D0 (en) 2004-04-20 2004-04-20 Therapeutic treatment
GB0408752.4 2004-04-20

Publications (1)

Publication Number Publication Date
CN1980688A true CN1980688A (zh) 2007-06-13

Family

ID=32344046

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800192369A Pending CN1980688A (zh) 2004-04-20 2005-04-20 使肿瘤细胞致死的人α-乳清蛋白(HAMLET)在治疗病毒感染中的应用

Country Status (6)

Country Link
US (1) US20070232550A1 (cg-RX-API-DMAC10.html)
EP (1) EP1765383A1 (cg-RX-API-DMAC10.html)
JP (1) JP2007533728A (cg-RX-API-DMAC10.html)
CN (1) CN1980688A (cg-RX-API-DMAC10.html)
GB (1) GB0408752D0 (cg-RX-API-DMAC10.html)
WO (1) WO2005102382A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113855787A (zh) * 2020-06-30 2021-12-31 北京大学 乳清蛋白作为冠状病毒广谱抑制剂的用途
CN115245562A (zh) * 2021-08-31 2022-10-28 合生元(广州)健康产品有限公司 用于抑制冠状病毒的组合物及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113827707B (zh) * 2021-09-30 2023-12-05 北京大学 a-乳白蛋白在抑制冠状病毒中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210464D0 (en) * 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113855787A (zh) * 2020-06-30 2021-12-31 北京大学 乳清蛋白作为冠状病毒广谱抑制剂的用途
CN115245562A (zh) * 2021-08-31 2022-10-28 合生元(广州)健康产品有限公司 用于抑制冠状病毒的组合物及其应用

Also Published As

Publication number Publication date
JP2007533728A (ja) 2007-11-22
US20070232550A1 (en) 2007-10-04
WO2005102382A1 (en) 2005-11-03
EP1765383A1 (en) 2007-03-28
GB0408752D0 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
KR100479669B1 (ko) Igf-1의레벨증가에유용한l-아세틸카르니틴,l-이소발레릴카르니틴,l-프로피오닐카르니틴의용도
RU2012136221A (ru) Доставка активных веществ
JP2004501164A (ja) 末梢動脈疾患の処置のための方法および組成物
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
AU734122B2 (en) Compositions for the treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)benzamide and lung surfactant
HUE031750T2 (en) A method of administering a pulmonary surfactant
JP2020502056A5 (cg-RX-API-DMAC10.html)
WO2001068125A2 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
US7713533B2 (en) Active complex of α-lactalbumin (HAMLET) and cofactor
US20070232550A1 (en) Use of Hamlet (Human Alpha-Lactalbumin Made Lethal to Tumour Cells) for Treating Viral Infections
ES2758674T3 (es) Uso de taurina en la prevención y/o tratamiento de enfermedades inducidas por los virus del género coronavirus y/o del género rotavirus
DK2504006T3 (en) FORMATIONS COMPREHENSIVE AMINO FOR THE TREATMENT OF CHRONIC obstructive pulmonary disease
AU2013231936B2 (en) Protein to promote blood vessel growth and uses thereof
ES2532089T3 (es) GH e IGF-1 para el tratamiento de trastornos del crecimiento
CN108135874B (zh) 用于治疗经历了选择性关节置换术的患者的疼痛的组合物
Lee Growth factors in oral and maxillofacial surgery: potentials and challenges
JP2007161702A (ja) 水性吸入用医薬組成物
JP4541642B2 (ja) 肺感染症および肺腫瘍を治療するためのリポペプチド類およびリポプロテイン類の使用
JP2007533728A5 (cg-RX-API-DMAC10.html)
JP2009502779A5 (cg-RX-API-DMAC10.html)
WO1996032960A1 (fr) Medicament preventif ou therapeutique, ou les deux, pour les affections ischemiques
ES2291274T3 (es) Composiciones de t3 estable y metodos de uso de las mismas.
KR20020061379A (ko) 성장 호르몬 분비 촉진제 조성물
JP2023525522A (ja) Covid-19の治療または予防用ペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CATANIA HAMLET MEDICINE CO., LTD.

Free format text: FORMER OWNER: HAMLET MEDICINE CO., LTD.

Effective date: 20080411

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080411

Address after: Copenhagen

Applicant after: Hamlet Pharma AB

Address before: Longde, Sweden

Applicant before: Hamlet Pharma AB

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication